| Not Yet Recruiting | Clinical Trial Evaluating Safety and Efficacy of Resomelagon on Dengue Infection (RESOVIR-2) NCT06917001 | Federal University of Minas Gerais | Phase 2 |
| Recruiting | A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years) NCT06579755 | Takeda | Phase 3 |
| Recruiting | International Registry of Dengue Infection in Congenital Bleeding Disorders (DengueCBDR) NCT07409857 | Mahidol University | — |
| Active Not Recruiting | A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults NCT07047521 | Takeda | Phase 3 |
| Enrolling By Invitation | To Assess the Efficacy of Carica Papaya Leaf Extract in Improving Platelet Counts Among Pediatric Patients Wit NCT07172100 | Ziauddin Hospital | Phase 2 |
| Not Yet Recruiting | Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections NCT07112846 | Hospital Israelita Albert Einstein | — |
| Enrolling By Invitation | Xpert® Tropical Fever Test on GeneXpert® Edge X System NCT07520279 | Cepheid | — |
| Recruiting | Risk Factors for Hospitalization and Transfusion Criteria in Patients With Dengue Virus Infection NCT07007585 | Jose Ivan Rodriguez de Molina Serrano | — |
| Recruiting | A Study of 2 Doses of Tetravalent Dengue Vaccine (TDV) in Infants and Toddlers NCT06665035 | Takeda | Phase 3 |
| Recruiting | A Study in Children and Teenagers to Learn if a TDV Dengue Vaccination Lowers the Chance of Hospital Stays for NCT06843226 | Takeda | — |
| Completed | A Study of Dengue Tetravalent Vaccine (TDV) in Healthy Participants in Japan NCT06741683 | Takeda | Phase 2 / Phase 3 |
| Completed | The Comparative Efficacy of Standard Treatment Plus Ribavirin vs Standard Treatment Alone in Preventing Clinic NCT06744777 | Khyber Medical University Peshawar | Phase 3 |
| Completed | Prediction of Infectious Diseases in LMICs Using Electronic Health Record Data NCT07432061 | Mahidol University | — |
| Recruiting | A Study to Monitor the Adverse Events of QDENGA Vaccine in Participants in Malaysia NCT06388785 | Takeda | — |
| Completed | Characteristics of Clinical Laboratory Indicators in Patients with Dengue Fever NCT06877039 | Foshan Hospital of Traditional Chinese Medicine | — |
| Completed | Effects of Carica Papaya Leaf Extract (CPLE) in the Outcome of Hospitalized Dengue Patients NCT06945679 | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Phase 1 / Phase 2 |
| Active Not Recruiting | Efficacy of Fresh Frozen Plasma (FFP) in Treating Thrombocytopenia in Dengue Patients NCT06642493 | Sheikh Hasina National Institute of Burn and Plastic Surgery | N/A |
| Recruiting | Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE) NCT04597437 | George Washington University | Phase 2 |
| Unknown | Role of Vitamin D in Prevention of Dengue Haemorrhagic Fever and Dengue Shock Syndrome NCT06071481 | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Phase 2 |
| Completed | Evaluation Study of Dengue RDTs NCT05580731 | Foundation for Innovative New Diagnostics, Switzerland | — |
| Unknown | Lymphocyte Count and High Fluorescent Count (HFLC) Correlate With Liver Disorder in Dengue Fever Patients NCT05407181 | Nurhasan Agung Prabowo | — |
| Terminated | Study of AT-752 in Patients With Dengue Infection NCT05466240 | Atea Pharmaceuticals, Inc. | Phase 2 |
| Suspended | Baromètre Santé Adulte 2021-2022 NCT05218304 | Agence Sanitaire et Sociale de Nouvelle Calédonie | N/A |
| Completed | Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Va NCT04313244 | Takeda | Phase 3 |
| Unknown | Prospective Study on the Risks of Dengue Fever for the Fetus. NCT04822441 | Centre Hospitalier Universitaire de la Réunion | — |
| Completed | Sylvatic Transmission of Zika, Dengue, and Chikungunya Viruses in Thailand and Cambodia NCT04434846 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Unknown | Mobile Point of Care Diagnostic Testing for Ebola Virus Disease in DRC NCT04235361 | University of Stirling | — |
| Completed | A Cluster-randomized Trial to EValuate the Efficacy of Wolbachia-InfecTed Aedes Aegypti Mosquitoes in Reducing NCT04514107 | National Institute of Allergy and Infectious Diseases (NIAID) | N/A |
| Unknown | New Tools for Predicting Capillary Leak Shock During Dengue Fever NCT04422782 | Centre Hospitalier de Cayenne | N/A |
| Active Not Recruiting | Surveillance of Suspected Dengue Cases for Access to Care for Subjects Identified as Seronegative or Undetermi NCT04113330 | Sanofi Pasteur, a Sanofi Company | — |
| Completed | Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose NCT03999996 | Takeda | Phase 3 |
| Completed | Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults NCT02741128 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Withdrawn | IC14 in Adult Patients With Dengue Fever NCT03875560 | Implicit Bioscience | Phase 2 |
| Completed | Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy Adults NCT03771963 | Takeda | Phase 3 |
| Completed | Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune NCT03746015 | Takeda | Phase 2 |
| Withdrawn | Celgosivir or Modipafant as Treatment for Adult Participants With Uncomplicated Dengue Fever in Singapore NCT02569827 | Singapore General Hospital | Phase 1 / Phase 2 |
| Completed | Investigating Vector-Borne Determinants of Aedes Transmitted Arboviral Infections in Cambodia: An Observationa NCT03534245 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue NCT03423173 | Takeda | Phase 3 |
| Terminated | Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subje NCT02992418 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine NCT02948933 | Sanofi Pasteur, a Sanofi Company | — |
| Completed | Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gard NCT02993757 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cerv NCT02979535 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Unknown | Dengue Serostatus Study in the Philippines NCT03465254 | University of the Philippines | — |
| Completed | Detection of Dengue Virus in Plasma of Patients in Nepal NCT03620487 | Karius, Inc. | — |
| Completed | Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Complet NCT02824198 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects NCT02628444 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedu NCT02623725 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Association of Host Genetics With Vaccine Efficacy and Study of Immune Correlates of Risk From a Tetravalent D NCT02827162 | Sanofi Pasteur, a Sanofi Company | — |
| Completed | The Clinical Epidemiology of Hospitalized Dengue Cases in Malaysia NCT02510638 | Clinical Research Centre, Malaysia | — |
| Completed | Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's Tetravalent Dengue Vaccine Candi NCT02425098 | Takeda | Phase 2 |
| Unknown | Ketotifen as a Treatment for Vascular Leakage During Dengue Fever NCT02673840 | National University Hospital, Singapore | Phase 4 |
| Completed | Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Hea NCT02302066 | Takeda | Phase 2 |
| Unknown | Studies on the Pathogen, Vector Control and Clinical Treatment of Dengue Fever in Guangzhou NCT02608047 | Guangzhou 8th People's Hospital | — |
| Completed | Factors Associated With Poor Dengue Outcomes in Malaysia NCT02510690 | Clinical Research Centre, Malaysia | — |
| Completed | Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) NCT02193087 | Takeda | Phase 2 |
| Unknown | Efficacy and Safety of Ivermectin Against Dengue Infection NCT02045069 | Mahidol University | Phase 2 / Phase 3 |
| Completed | Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue NCT01943825 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Effi NCT01983553 | Sanofi Pasteur, a Sanofi Company | — |
| Completed | Impact of SC vs IM Administration of DENVax (TDV) on Safety and Immunogenicity NCT01728792 | Takeda | Phase 1 |
| Completed | A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in NCT01702857 | U.S. Army Medical Research and Development Command | Phase 1 |
| Completed | A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in NCT01666652 | U.S. Army Medical Research and Development Command | Phase 1 |
| Completed | Clinical Specimens Testing Program of Dengue Antigen Detection Reagents NCT01917422 | Kaohsiung Medical University Chung-Ho Memorial Hospital | — |
| Completed | Celgosivir as a Treatment Against Dengue NCT01619969 | Singapore General Hospital | Phase 1 / Phase 2 |
| Completed | Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India NCT01550289 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Unknown | Chinese and Western Medicine Treatment of Fever Associated With Bleeding Symptoms NCT01973855 | Guangzhou 8th People's Hospital | Phase 2 |
| Completed | Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vacc NCT01488890 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Safety Study of a Vaccine (DENV-1 PIV) to Prevent Dengue Disease NCT01502735 | U.S. Army Medical Research and Development Command | Phase 1 |
| Completed | Evaluation of the Safety and the Ability of a DNA Vaccine to Protect Against Dengue Disease NCT01502358 | U.S. Army Medical Research and Development Command | Phase 1 |
| Completed | International Research Consortium on Dengue Risk Assessment, Management, and Surveillance NCT01550016 | University of Heidelberg Medical Center | — |
| Completed | Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children NCT01477671 | Sanofi Pasteur, a Sanofi Company | — |
| Completed | Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin Am NCT01374516 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia NCT01373281 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia NCT01254422 | Sanofi | Phase 3 |
| Completed | Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue NCT01224639 | Inviragen Inc. | Phase 1 |
| Completed | Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia NCT01134263 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Laboratory Diagnosis and Prognosis of Severe Dengue NCT01421732 | Oxford University Clinical Research Unit, Vietnam | — |
| Completed | Role of Andi-d in Dengue Fever: a Pilot Study NCT01443247 | Post Graduate Institute of Medical Education and Research, Chandigarh | N/A |
| Completed | Study of Febrile Illness for Dengue-Endemic Areas in Latin America NCT01293331 | Sanofi | — |
| Completed | Prospective Surveillance of Febrile Illness for Dengue-Endemic Areas in Asia NCT01218906 | Sanofi | — |
| Completed | A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines NCT01064141 | Sanofi | Phase 2 |
| Completed | Adult Dengue Platelet Study NCT01030211 | Tan Tock Seng Hospital | N/A |
| Completed | Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin NCT00993447 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31-7164) in Healthy Adults NCT00831012 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Diagnosis and Characterization of Dengue Fever in Children NCT00946218 | St. Jude Children's Research Hospital | — |
| Completed | Study of HBV-001 D1 in Healthy Adults NCT00936429 | Hawaii Biotech, Inc. | Phase 1 |
| Completed | Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore NCT00880893 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects NCT00875524 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Efficacy and Safety of Dengue Vaccine in Healthy Children NCT00842530 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Safety and Immune Response to Two Doses of rDEN2/4delta30 Dengue Vaccine NCT00920517 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years NCT00788151 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults NCT00740155 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in th NCT00617344 | Sanofi | Phase 2 |
| Completed | A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and Children NCT00468858 | U.S. Army Medical Research and Development Command | Phase 2 |
| Unknown | Investigation of the Immuno-regulation and Viral Hepatitis Among Patients With or After Dengue Fever Infection NCT00688389 | Kaohsiung Medical University Chung-Ho Memorial Hospital | — |
| Completed | Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects NCT00730288 | Sanofi | Phase 2 |
| Completed | Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-200,201) in Healthy Adults NCT00270699 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Safety of and Immune Response to a Dengue Virus Vaccine (rDEN2/4delta30[ME]) in Healthy Adults NCT00094705 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Safety of and Immune Response to a Dengue Virus Vaccine (rDEN1delta30) in Healthy Adults NCT00089908 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children NCT00384670 | U.S. Army Medical Research and Development Command | Phase 1 / Phase 2 |